Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT06267729




Registration number
NCT06267729
Ethics application status
Date submitted
5/01/2024
Date registered
20/02/2024
Date last updated
28/05/2024

Titles & IDs
Public title
Study of AZD0754 in Participants With Metastatic Prostate Cancer
Scientific title
A Phase I/II Open Label Study to Evaluate the Safety, Cellular Kinetics, and Efficacy of AZD0754, a Chimeric Antigen Receptor (CAR) T-cell Therapy Directed Against STEAP2, in Adult Participants With Metastatic Prostate Cancer: APOLLO
Secondary ID [1] 0 0
D9660C00001
Universal Trial Number (UTN)
Trial acronym
APOLLO
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Metastatic Prostate Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Prostate

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Other interventions - AZD0754

Experimental: AZD0754 - AZD0754 monotherapy for treatment of participants with metastatic prostate cancer.


Other interventions: AZD0754
Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to produce AZD0754.
During AZD0754 production, subjects may receive bridging therapy for disease control. Upon successful generation of AZD0754 product, subjects will receive treatment with AZD0754 therapy.
Study treatment will include lymphodepleting chemotherapy followed by one dose of AZD0754 administered by intravenous (IV) infusion.
Intervention code [1] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Incidence of participants with Dose-limiting Toxicity (DLTs)/DLT-like events, Adverse Events (AEs), including Adverse Events of Special Interest (AESIs) and Serious Adverse Events (SAEs).
Timepoint [1] 0 0
Through study completion, an average of 2 years
Primary outcome [2] 0 0
Presence of replication-competent lentivirus (RCL) in peripheral blood samples
Timepoint [2] 0 0
Through study completion, an average of 2 years
Secondary outcome [1] 0 0
Prostate-specific antigen (PSA) response rate - PSA50
Timepoint [1] 0 0
Through study completion, an average of 2 years
Secondary outcome [2] 0 0
PSA response rate - PSA90
Timepoint [2] 0 0
Through study completion, an average of 2 years
Secondary outcome [3] 0 0
Duration of PSA Response (DoPSA50, DoPSA90)
Timepoint [3] 0 0
Through study completion, an average of 2 years
Secondary outcome [4] 0 0
Durable PSA Response Rate (DRRPSA50, DRRPSA90)
Timepoint [4] 0 0
Through study completion, an average of 2 years
Secondary outcome [5] 0 0
Time to PSA Response (TTPSA50, TTPSA90)
Timepoint [5] 0 0
Through study completion, an average of 2 years
Secondary outcome [6] 0 0
Time to PSA Progression (TTPSAP50, TTPSAP90)
Timepoint [6] 0 0
Through study completion, an average of 2 years
Secondary outcome [7] 0 0
Best Overall Response (BOR)
Timepoint [7] 0 0
Through study completion, an average of 2 years
Secondary outcome [8] 0 0
Objective Response Rate (ORR)
Timepoint [8] 0 0
Through study completion, an average of 2 years
Secondary outcome [9] 0 0
Time to Response (TTR)
Timepoint [9] 0 0
Through study completion, an average of 2 years
Secondary outcome [10] 0 0
Duration of Response (DoR)
Timepoint [10] 0 0
Through study completion, an average of 2 years
Secondary outcome [11] 0 0
Durable Response Rate (DRR)
Timepoint [11] 0 0
Through study completion, an average of 2 years
Secondary outcome [12] 0 0
Disease Control Rate (DCR)
Timepoint [12] 0 0
12 and 24 weeks after AZD0754 infusion
Secondary outcome [13] 0 0
Percentage change in tumor size
Timepoint [13] 0 0
Through study completion, an average of 2 years
Secondary outcome [14] 0 0
Radiographic Progression-free Survival (rPFS)
Timepoint [14] 0 0
Through study completion, an average of 2 years
Secondary outcome [15] 0 0
Overall Survival (OS)
Timepoint [15] 0 0
Through study completion, an average of 2 years
Secondary outcome [16] 0 0
Time from AZD0754 Infusion to the first Symptomatic Skeletal-related Events (SSRE)
Timepoint [16] 0 0
Through study completion, an average of 2 years
Secondary outcome [17] 0 0
Pharmacokinetics - maximum observed serum concentration (Cmax) of AZD0754
Timepoint [17] 0 0
Through study completion, an average of 2 years
Secondary outcome [18] 0 0
Pharmacokinetics - time taken to reach maximum serum concentration (Tmax) of AZD0754
Timepoint [18] 0 0
Through study completion, an average of 2 years
Secondary outcome [19] 0 0
Pharmacokinetics - Last measurable serum concentration (Clast) of AZD0754
Timepoint [19] 0 0
Through study completion, an average of 2 years
Secondary outcome [20] 0 0
Pharmacokinetics - time of last measurable serum concentration (Tlast) of AZD0754
Timepoint [20] 0 0
Through study completion, an average of 2 years
Secondary outcome [21] 0 0
Pharmacokinetics - Exposure of AZD0754
Timepoint [21] 0 0
Through study completion, an average of 2 years
Secondary outcome [22] 0 0
Biomarker - STEAP2 expression in Tumor
Timepoint [22] 0 0
Through study completion, an average of 2 years

Eligibility
Key inclusion criteria
Age

1. Participant must be 18 years or older at the time of signing the informed consent
form.

Type of Participant and Disease Characteristics

2. Participants with:

1. A histologically confirmed diagnosis of metastatic adenocarcinoma of the prostate
without known neuroendocrine differentiation or small cell features.

2. Castration-resistant prostate cancer as defined by disease progression despite
castration by orchiectomy or ongoing luteinising hormone-releasing hormone
analogue. Participants receiving medical castration therapy with gonadotropin
releasing hormone analogues should continue this treatment during the study.

3. Measurable PSA >/=1 ng/mL AND

4. Evidence of progression within 6 months prior to screening according to one of
the following:

(i) Radiographic disease progression in soft tissue based on Response Evaluation
Criteria in Solid Tumours Version 1.1 criteria with or without PSA progression as per
Prostate Cancer Working Group Criteria 3 (PCWG3) (ii) Radiographic disease progression
in bone defined as the appearance of 2 or more new bone lesions on bone scan as per
Prostate Cancer Working Group Criteria 3 (PCWG3).

3. Participant has previously received a NHA (ie, abiraterone, enzalutamide, apalutamide,
darolutamide) and taxane as part of their treatment for prostate cancer (whether
before or in the metastatic castration-resistant setting) or be ineligible for or
refuse taxanes.

4. For participants with HRR deficiency disease or breast cancer gene mutated disease,
they disease must also have received a PARP inhibitor or be intolerant of this
therapy.

5. For participants who have high microsatellite instability or deficient DNA mismatch
repair they must also have received at least one line of checkpoint inhibitors (ie,
pembrolizumab), not be eligible for, or be intolerant to therapy as per NCCN or local
treatment guidelines.

6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 prior to
apheresis.

7. Minimum life expectancy of > 12 weeks prior to apheresis in the opinion of the
Investigator

8. Adequate organ and marrow function.

9. Consent and provision of tumour material to assess STEAP2 expression and other
correlative biomarkers retrospectively with pre- and post-treatment biopsies. Fresh
baseline and on-treatment biopsies are required unless these are deemed medically
unfeasible. If the participant is unable to undergo fresh biopsy, an archival tumour
sample will be required (age of biopsy cannot be greater than 10 years).
Minimum age
18 Years
Maximum age
130 Years
Sex
Males
Can healthy volunteers participate?
No
Key exclusion criteria
1. Participants with weight less than 42 kg

2. History of another primary malignancy except for malignancy treated with curative
intent with no known active disease (= 2 years) before the first dose of study
intervention and of low potential risk for recurrence. Such exceptions include
non-melanoma cancer of the skin that has undergone curative therapy or adequately
treated carcinoma in situ without evidence of disease.

3. Participants with known brain metastases.

4. Prior solid organ transplantation.

5. Active or prior documented autoimmune or inflammatory disorders (including but not
limited to inflammatory bowel disease [eg, colitis, Crohn's disease], diverticulitis,
systemic lupus erythematosus, Wegener's syndrome, myasthenia gravis, Graves' disease,
rheumatoid arthritis, hypophysitis, uveitis, autoimmune pneumonitis, autoimmune
nephritis, or nephropathy, etc). The following are exceptions to this criterion:

1. Participants with vitiligo or autoimmune alopecia.

2. Participants with autoimmune hypothyroidism (eg, following Hashimoto thyroiditis)
stable on hormone replacement.

3. Any chronic inflammatory or autoimmune skin condition that does not require
systemic therapy.

4. Participants without active disease in the last 5 years may be included, but only
after consultation with the Sponsor.

5. Participants with coeliac disease controlled by diet alone.

6. Stroke, intracranial haemorrhage, or seizure within 6 months of apheresis.

7. Cardiac arrhythmias, (such as multifocal premature ventricular contractions, bigeminy,
trigeminy, ventricular tachycardia), which are symptomatic or require treatment
(Common Terminology Criteria for Adverse Events [CTCAE] Grade 3) unless controlled by
pacemaker (discussion with the Study Physician required); symptomatic or uncontrolled
atrial fibrillation despite treatment, or asymptomatic sustained ventricular
tachycardia.

8. Investigator judgement of one or more of the following:

1. Mean resting corrected QT interval > 470 ms, obtained from triplicate
electrocardiograms (ECGs) performed at screening.

2. History of QT prolongation associated with other medications that required
discontinuation of that medication, or any current concomitant medication known
to prolong the QT interval.

3. Congenital long QT syndrome, family history of long QT syndrome, or unexplained
sudden death under 40 years of age in first-degree relatives.

9. Uncontrolled intercurrent illness including, but not limited to, ongoing or active
known infection, cardiomyopathy of any aetiology, symptomatic congestive heart failure
defined by New York Heart Association class = 3), interstitial lung disease,
uncontrolled hypertension, uncontrolled diabetes mellitus, unstable angina pectoris,
history of myocardial infarction within the past 6 months prior to apheresis.

10. Active, uncontrolled epilepsy. Participants without active/uncontrolled epilepsy in
the last 5 years may be included.

11. Persistent toxicities (CTCAE Grade = 2) caused by previous anticancer therapy,
excluding alopecia. Participants with irreversible toxicity that is not reasonably
expected to be exacerbated by study intervention may be included (eg, hearing loss)
after consultation with the Study Physician or Medical Monitor. Participants with
Grade 2 neuropathy will be evaluated on a case-by-case basis after consultation with
the Study Physician or Medical Monitor.

12. Seropositive for human immunodeficiency virus (HIV).

13. Active hepatitis C infection (HCV). Participants testing positive for HCV antibody are
eligible only if the polymerase chain reaction is negative for HCV RNA.

14. Participants with hepatitis B virus (HBV) may be included under the following
circumstances:

1. Negative for hepatitis B surface antigen (HbsAg) and positive for anti-HBc
antibody

2. Positive for HbsAg, but for > 6 months have had normal transaminases and HBV DNA
levels between 0 - 2000 IU/mL (inactive carrier state) and willing to start and
maintain antiviral treatment for at least the duration of the study.

3. HBV DNA levels > 2000 IU/mL but on prophylactic antiviral treatment for the past
3 months and will maintain the antiviral treatment during the study.

15. Local requirements for the testing for infectious diseases and exclusions of
applicable participants should be followed per local regulations.

Prior/Concomitant Therapy

16. Participants may not receive full-dose long acting oral or parenteral anticoagulants
or thrombolytic agents for therapeutic (as opposed to prophylactic) purpose from the
time of informed consent to 28-days post infusion of AZD0754. Use of short acting
direct oral anticoagulants for therapeutic and prophylactic purposes are permitted.

17. Any concomitant medications known to be associated with Torsades de Points within 14
days prior and 28 days after AZD0754 infusion.

18. Received the following:

1. Major surgery within 2 weeks prior to apheresis, or planned major surgery within
4 weeks of the study treatment administration (Note: participants with planned
surgical procedures to be conducted under local anaesthesia may participate after
discussion with the Sponsor).

2. Steroids (except inhaled steroids) or other immunomodulators (including
interleukins, interferons, and thymosins) of systemic therapeutic dose, and
systemic corticosteroids at doses exceeding 10 mg/day of prednisone or equivalent
< 7 days prior to apheresis.

19. Receipt of the last dose of anticancer therapy (chemotherapy, immunotherapy, endocrine
therapy targeted therapy, biologic therapy, tumour embolisation, or monoclonal
antibodies, investigational product) within 5 half-lives or = 21 days (whichever is
shorter) prior to apheresis. Radiotherapy within 14 days. However, if the radiation
portal covered = 5% of the bone marrow reserve, the participant is eligible
irrespective of the end date of radiotherapy. If sufficient washout time has not
occurred due to the schedule or PK properties of an agent, a longer washout period
will be required, as agreed by AstraZeneca and the Investigator.

20. Any concurrent anticancer treatment with the following exceptions:

1. Protocol-defined LDC

2. Hormonal therapy for non cancer-related conditions (eg, hormone replacement
therapy)

3. Androgen deprivation therapy with a luteinising-hormone replacement hormone
agonist/antagonist is required if needed to maintain testosterone level in the
castration range (levels < 50 ng/dL) and should be continued (unless bilateral
orchiectomy) throughout the trial. Following apheresis, bridging therapy is
permitted (if required) as outlined in Section 6.1.2

21. Participants should not have received any live vaccines within 30 days prior to
apheresis. Participants can receive coronavirus (COVID)-19 vaccines, at the discretion
of the Investigator, following a benefit/risk evaluation for the individual
participant and in accordance with local rules and regulations and vaccination
guidelines. Note: If a COVID-19 vaccine is administered, it should ideally be done at
least one week prior to LDC or after completion of the DLT period.

Prior/Concurrent Clinical Study Experience

22. Prior treatment with a CAR-T therapy directed at any target or any therapy that is
targeted to STEAP2.

23. Participants with a known life-threatening allergy, hypersensitivity, or intolerance
to AZD0754 or any of the excipients of the product, including dimethylsulfoxide.

Study design
Purpose of the study
Treatment
Allocation to intervention
N/A
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 1/Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
12/03/2024
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
24/05/2027
Actual
Sample size
Target
60
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Research Site - East Melbourne
Recruitment postcode(s) [1] 0 0
3002 - East Melbourne
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Florida
Country [3] 0 0
United States of America
State/province [3] 0 0
Georgia
Country [4] 0 0
United States of America
State/province [4] 0 0
Missouri
Country [5] 0 0
United States of America
State/province [5] 0 0
New Jersey
Country [6] 0 0
United States of America
State/province [6] 0 0
New York
Country [7] 0 0
United States of America
State/province [7] 0 0
Pennsylvania
Country [8] 0 0
United States of America
State/province [8] 0 0
Texas

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
AstraZeneca
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to evaluate the safety, tolerability, and antitumour activity of
AZD0754 CAR T-cell therapy in participants with metastatic prostate cancer.
Trial website
https://clinicaltrials.gov/ct2/show/NCT06267729
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
AstraZeneca Clinical Study Information Center
Address 0 0
Country 0 0
Phone 0 0
1-877-240-9479
Fax 0 0
Email 0 0
information.center@astrazeneca.com
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT06267729